title: Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation.
abstract: The role of antiviral antibody in controlling the acute and latent phases of herpes simplex virus (HSV) infection in sensory ganglia of mice was studied in vitro and in vivo. Organ cultures of ganglia inoculated in vitro with HSV produced infectious virus for at least 3 weeks. In the presence of antiviral antibody, the titre of virus was markedly reduced, but the infection was not eliminated. Similarly, passive administration of antibody to HSV-infected immunodeficient (nude) mice reduced the virus titre but did not eliminate the acute phase of the ganglionic infection. Suppression of the cell-mediated immune response in latently infected immunocompetent mice by treatment with cyclophosphamide and/or X-irradiation resulted in reactivation of HSV in up to 70% of the animals. Reactivation was demonstrated by recovering infectious virus in cell-free homogenates of ganglia and eye globes and by finding virus antigens in ganglia by immunofluorescent staining. Reactivation occurred both in vitro and in vivo in the presence of high concentrations of neutralizing antibody. It is concluded that antibody alone is not sufficient to eliminate the acute phase of the ganglionic infection and that cytotoxic agents known to suppress the host's cellular immune response can reactivate virus in the presence of neutralizing antibody.
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D005724:Ganglia / Q000382:microbiology*; D006561:Herpes Simplex / Q000276:immunology / Q000382:microbiology*; D007165:Immunosuppression Therapy; D051379:Mice; D009924:Organ Culture Techniques; D018139:Simplexvirus / Q000254:growth & development* / Q000276:immunology; D012668:Trigeminal Ganglion; D014779:Virus Replication / Q000187:drug effects / Q000528:radiation effects; D014965:X-Rays
chemical_list: D000914:Antibodies, Viral; D003520:Cyclophosphamide